AtriCure (ATRC) Misses Q1 EPS by 2c; Receives Conditional Approval of DEEP AF Feasibility Trial From FDA
Tweet Send to a Friend
AtriCure (Nasdaq: ATRC) reports a Q1 loss of $0.13, 2 cents worse than the analyst estimate of ($0.11). Revenue ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
